RFA-PS-23-005: Expanding Rapid Initiation of Antiretroviral Therapy in Non-traditional Settings: Emergency Department
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2023.
Centers for Disease Control and Prevention - ERA offered grants of up to $500,000 (at least $400,000) to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 3 awards worth $6.0 million in total. Applications closed on March 27, 2023.
From the official notice on Grants.gov, last changed March 22, 2023. Checked November 7, 2026.
- Award ceiling$500,000
- Award floor$400,000
- Total funding$6.0 million
- Expected awards3
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | January 12, 2023 |
|---|---|
| Deadline | March 27, 2023 |
| Archived by Grants.gov | April 25, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 14 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
Is this a realistic fit?
- Past Prevention of Disease, Disability, and Death by Infectious Diseases awards averaged $1.9 million; this notice allows up to $500,000 per award.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity is to support implementation research on the rapid or immediate initiation of HIV antiretroviral therapy (ART) for persons newly diagnosed with HIV or for persons with HIV (PWH) returning to care in Emergency Department (ED) settings. The rapid ART model, defined as immediate diagnosis, linkage to care, and ART initiation on the same day as a new HIV diagnosis or return to care, offers an accelerated entry into HIV medical care. The ED offers a unique setting to immediately engage with patients who are not accessing existing HIV services. The implementation research supported by this funding will evaluate acceptability, perceived barriers and facilitators, feasibility, sustainability, and HIV care continuum outcomes of deploying rapid ART models in ED settings. Applied research resulting from this funding is expected to decrease HIV infections and more rapidly reach viral suppression among PWH.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before
From fiscal 2021 to 2025, Prevention of Disease, Disability, and Death by Infectious Diseases (93.084) awarded $241 million across 128 grant awards, an average of $1.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Puerto Rico Science, Technology, and Research Trust | Puerto Rico | 4 | $14.5 million |
| Massachusetts Department of Public Health | Massachusetts | 1 | $11.6 million |
| Emory University | Georgia | 3 | $11.5 million |
| Uganda Virus Research Institute | 1 | $8.7 million | |
| Ponce Medical School Foundation Inc | Puerto Rico | 2 | $8.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-PS-23-005 still open?
No. It closed on March 27, 2023. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Expanding Rapid Initiation of Antiretroviral Therapy in Non-traditional Settings: Emergency Department?
Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
What is the deadline for Expanding Rapid Initiation of Antiretroviral Therapy in Non-traditional Settings: Emergency Department?
Closed March 27, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each. About $6.0 million in total across about 3 awards.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before?
The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)